Huiqiang Huang, Rong Tao, Siguo Hao, Yu Yang, Hong Cen, Hui Zhou, Ye Guo, Liqun Zou, Junning Cao, Yunhong Huang, Jie Jin, Liling Zhang, Haiyan Yang, Xiaojing Xing, Huilai Zhang, Yanyan Liu, Kaiyang Ding, Qinzhou Qi, Xiaoli Zhu, Dan Zhu, Siyuan Wang, Teng Fang, Hangjun Dai, Qingmei Shi, Jason Yang
PURPOSE: Relapsed or refractory extranodal natural killer/T-cell lymphoma (R/R ENKTL) is a rare and aggressive type of non-Hodgkin lymphoma with limited treatment options. This phase II study evaluated the efficacy and safety of sugemalimab, an anti-PD-L1 monoclonal antibody, in R/R ENKTL. METHODS: Eligible patients received sugemalimab 1,200 mg intravenously once every 3 weeks for up to 24 months or until progression, death, or study withdrawal. The primary end point was objective response rate (ORR) assessed by an independent radiologic review committee...
March 30, 2023: Journal of Clinical Oncology